Paroxysmal nocturnal hemoglobinuria Clinical Trials

28 recruitingLast updated: June 18, 2026

There are 28 actively recruiting paroxysmal nocturnal hemoglobinuria clinical trials across 34 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Seoul, South Korea, London, United Kingdom, Paris, France. Updated daily from ClinicalTrials.gov.


Paroxysmal nocturnal hemoglobinuria Trials at a Glance

28 actively recruiting trials for paroxysmal nocturnal hemoglobinuria are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Seoul, London, and Paris. Lead sponsors running paroxysmal nocturnal hemoglobinuria studies include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, and Haisco Pharmaceutical Group Co., Ltd..

Browse paroxysmal nocturnal hemoglobinuria trials by phase

Treatments under study

About Paroxysmal nocturnal hemoglobinuria Clinical Trials

Looking for clinical trials for Paroxysmal nocturnal hemoglobinuria? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Paroxysmal nocturnal hemoglobinuria trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Paroxysmal nocturnal hemoglobinuria clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria, PNHSevere Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1Phase 2

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting
Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals80 enrolled14 locationsNCT06931691
Recruiting
Phase 3

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals35 enrolled13 locationsNCT07154745
Recruiting

Danicopan PMS in Korea

Paroxysmal nocturnal hemoglobinuria
AstraZeneca8 enrolled5 locationsNCT07457151
Recruiting

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals50 enrolled10 locationsNCT07229235
Recruiting
Phase 1

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH - Paroxysmal Nocturnal Hemoglobinuria
Shanghai Lanyi Therapeutics Co., Ltd.24 enrolled2 locationsNCT07256301
Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Phase 3

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967
Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria
Jiangsu Hansoh Pharmaceutical Co., Ltd.50 enrolled1 locationNCT07470762
Recruiting

Specified Drug-use Surveillance of Fabhalta Capsules

Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals100 enrolled92 locationsNCT06606314
Recruiting
Phase 1

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

Paroxysmal Nocturnal Hemoglobinuria, PNHComplement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd.88 enrolled1 locationNCT07462780
Recruiting
Phase 1Phase 2

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled7 locationsNCT07187401
Recruiting
Phase 3

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled43 locationsNCT05744921
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 3

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

PNHExtravascular HemolysisParoxysmal nocturnal hemoglobinuria
Alexion Pharmaceuticals, Inc.6 enrolled4 locationsNCT06449001
Recruiting
Phase 1

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

Paroxysmal Nocturnal Hemoglobinuria, PNH
Haisco Pharmaceutical Group Co., Ltd.24 enrolled1 locationNCT07152288
Recruiting

Home Reported Outcomes in PNH

Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals128 enrolled1 locationNCT06411626
Recruiting
Phase 2

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria, PNHParoxysmal Hemoglobinuria
Apellis Pharmaceuticals, Inc.12 enrolled12 locationsNCT04901936